Amivantamab联合lazertinib一线治疗EGFR敏感突变晚期NSCLC:评MARIPOSA研究  

Review of MARIPOSA Trial:Amivantamab Plus Lazertinib as First⁃Line Treatment in Patients With EGFR⁃Mutated Non⁃Small Cell Lung Cancer

作　　者：谢聪颖[1] 刘嘉淇 XIE Cong-ying;LIU Jia-qi(Department of Radiation and Medical Oncology,The First Affiliated Hospital of Wenzhou Medical University,Zhejiang Wenzhou 325000,China;不详)

机构地区：[1]温州医科大学附属第一医院放化疗科,浙江温州325000 [2]广东省肺癌研究所,南方医科大学附属广东省人民医院(广东省医学科学院),广州510080

出　　处：《循证医学》2024年第1期20-25,共6页The Journal of Evidence-Based Medicine

摘　　要：1文献来源Cho BC,Felip E,Spira AI,et al.Amivantamab plus lazertinib versus osimertinib as first⁃line treatment in patients with EGFR⁃mutated,advanced non⁃small cell lung cancer(NSCLC):primary results from MARIPOSA,a phaseⅢ,global,randomized,controlled trial[J].Ann Oncol,2023,34(2S):S1306.

关 键 词：非小细胞肺癌 EGFR突变 amivantamab lazertinib 一线治疗 

分 类 号：R734.2[医药卫生—肿瘤]